ALLO
Price
$1.70
Change
+$0.06 (+3.66%)
Updated
Jan 14 closing price
Capitalization
382.04M
48 days until earnings call
Intraday BUY SELL Signals
FATE
Price
$1.07
Change
+$0.05 (+4.90%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
117.66M
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALLO vs FATE

Header iconALLO vs FATE Comparison
Open Charts ALLO vs FATEBanner chart's image
Allogene Therapeutics
Price$1.70
Change+$0.06 (+3.66%)
Volume$4.63M
Capitalization382.04M
Fate Therapeutics
Price$1.07
Change+$0.05 (+4.90%)
Volume$59.41K
Capitalization117.66M
ALLO vs FATE Comparison Chart in %
ALLO
Daily Signal:
Gain/Loss:
FATE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALLO vs. FATE commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ALLO: $1.70 vs. FATE: $1.08)
Brand notoriety: ALLO and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 150% vs. FATE: 106%
Market capitalization -- ALLO: $382.04M vs. FATE: $124.58M
ALLO [@Biotechnology] is valued at $382.04M. FATE’s [@Biotechnology] market capitalization is $124.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALLO and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 6 TA indicator(s) are bullish while FATE’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 6 bullish, 4 bearish.
  • FATE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than FATE.

Price Growth

ALLO (@Biotechnology) experienced а +14.09% price change this week, while FATE (@Biotechnology) price change was -2.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

ALLO is expected to report earnings on Mar 04, 2026.

FATE is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($382M) has a higher market cap than FATE($118M). ALLO YTD gains are higher at: 24.088 vs. FATE (3.806). FATE has higher annual earnings (EBITDA): -145.34M vs. ALLO (-198.19M). ALLO has more cash in the bank: 252M vs. FATE (215M). ALLO (77.1M) and FATE (79.2M) have identical debt. FATE has higher revenues than ALLO: FATE (7.14M) vs ALLO (0).
ALLOFATEALLO / FATE
Capitalization382M118M324%
EBITDA-198.19M-145.34M136%
Gain YTD24.0883.806633%
P/E RatioN/AN/A-
Revenue07.14M-
Total Cash252M215M117%
Total Debt77.1M79.2M97%
FUNDAMENTALS RATINGS
ALLO vs FATE: Fundamental Ratings
ALLO
FATE
OUTLOOK RATING
1..100
1612
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4382
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (12) in the Biotechnology industry is significantly better than the same rating for ALLO (96). This means that FATE’s stock grew significantly faster than ALLO’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that FATE’s stock grew similarly to ALLO’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as ALLO (97). This means that FATE’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for FATE (82). This means that ALLO’s stock grew somewhat faster than FATE’s over the last 12 months.

ALLO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as FATE (100). This means that ALLO’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOFATE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signal:
Gain/Loss:
FATE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ERELY6.410.84
+15.13%
Eregli Demir Ve Celik Fabrikal
CKISF7.52N/A
N/A
CK Infrastructure Holdings Limited
ZLDAF0.27N/A
N/A
Zelira Therapeutics Ltd.
APPCF0.25N/A
N/A
Apac Resources Ltd
TTNMF1.18N/A
-0.25%
Titanium Transportation Group

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+3.66%
BEAM - ALLO
53%
Loosely correlated
+2.49%
CRSP - ALLO
51%
Loosely correlated
+1.26%
RXRX - ALLO
47%
Loosely correlated
+3.41%
FATE - ALLO
45%
Loosely correlated
+5.88%
AXON - ALLO
44%
Loosely correlated
-1.92%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CRBU. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-4.67%
CRBU - FATE
49%
Loosely correlated
+0.63%
MGX - FATE
47%
Loosely correlated
-1.71%
RXRX - FATE
47%
Loosely correlated
-2.49%
ALLO - FATE
46%
Loosely correlated
-1.80%
NKTX - FATE
45%
Loosely correlated
-5.96%
More